As GSTM1 null genotype is widely observed in humans (Warholm et al., 1981; Rebbeck, 1997; Cotton et al., 2000; Geisler and Olshan, 2001; Josephy, 2010) and has been reported as a risk factor for brain disorders associated with inflammation, such as Alzheimer’s disease (AD) (Piacentini et al., 2012; Liu et al., 2015; Wang et al., 2016; Jafarian et al., 2018), it is tempting to speculate that human GST null genotypes may impact neuroinflammatory responses across individuals, causing severer inflammatory phenotypes in subpopulations of patients with these brain disorders. Here, GSTM1 is linked to early-onset autosomal dominant Alzheimer disease.